Selexis CHO Cells in Suspension-1

Gene to GMP

With GENE to GMP™ in 9 Months, we can help you achieve faster time-to-market while helping you lower the manufacturing costs of your promising drug candidates.

In June 2017, JSR Life Sciences acquired Selexis as part of JSR’s commitment to offer industry partners best-in-class contract development manufacturing (CDMO) services. Selexis SA and KBI Biopharma, which was acquired by JSR in 2015, have joined forces to provide industry partners “GENE to GMP in 9 Months” — the most robust and fastest service offering for the biopharmaceutical industry.

With GENE to GMP in 9 months, we are committed to our partners’ satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

> LEARN MORE ABOUT GENE TO GMP

Gene-to-GMP-Production-Timeline-Typical-mAb-Monoclonal-Antibody-2019MAR15-V05

 
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bi-specific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis-Website-Test-Image-Container 1

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.

Learn More
Selexis-Website-Test-Image-Container 2

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis-Website-Test-Image-Container 3

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 140 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

Latest News

June 1, 2021

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Read More
May 27, 2021

Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

Read More

Copyright© 2021 Selexis SA. All Rights Reserved.